There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
Type | HazMat fee for 500 gram (Estimated) |
Excepted Quantity | USD 0.00 |
Limited Quantity | USD 15-60 |
Inaccessible (Haz class 6.1), Domestic | USD 80+ |
Inaccessible (Haz class 6.1), International | USD 150+ |
Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |
Structure of Bendamustine
CAS No.: 16506-27-7
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Bendamustine is a DNA cross-linking agent.
Synonyms: SDX-105 free base
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 16506-27-7 |
Formula : | C16H21Cl2N3O2 |
M.W : | 358.26 |
SMILES Code : | O=C(O)CCCC1=NC2=CC(N(CCCl)CCCl)=CC=C2N1C |
Synonyms : |
SDX-105 free base
|
MDL No. : | MFCD00866481 |
InChI Key : | YTKUWDBFDASYHO-UHFFFAOYSA-N |
Pubchem ID : | 65628 |
GHS Pictogram: |
![]() ![]() |
Signal Word: | Danger |
Hazard Statements: | H301-H311-H331-H341 |
Precautionary Statements: | P201-P202-P261-P264-P270-P271-P280-P302+P352-P304+P340-P308+P313-P310-P330-P361-P403+P233-P405-P501 |
Class: | 6.1 |
UN#: | 2811 |
Packing Group: | Ⅲ |
Description |
Bendamustine (SDX-105 free base), a purine analogue, acts as a DNA cross-linking agent, activating DNA-damage stress response and apoptosis. It possesses potent alkylating, anticancer, and antimetabolite properties [1].
|
Target |
|
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
U251MG | 5.5-65.3 μM | BDM retains its cytotoxic activity against both MGMT negative and TMZ-resistant cell lines | PMC5830080 | |
HEK293T cells | 20, 10, 5 µM | 48 hours | Detect the transcriptional activation effect of VDR on the CYP24A1 promoter | PMC5477689 |
THP-1 cells | 100 µM | 2 hours | Validate the binding of Vitexin to VDR protein through CETSA and DARTS experiments | PMC5477689 |
U87MG | 5.5-65.3 μM | BDM retains its cytotoxic activity against both MGMT negative and TMZ-resistant cell lines | PMC5830080 | |
T98G | 5.5-65.3 μM | BDM retains its cytotoxic activity against both MGMT negative and TMZ-resistant cell lines | PMC5830080 | |
KARPAS-422 | 200 µM | 1.5 days | To evaluate the cytotoxicity of Bendamustine on DLBCL cells, results showed significant inhibition of cell viability. | PMC11551994 |
SU-DHL2 | 200 µM | 1.5 days | To evaluate the cytotoxicity of Bendamustine on DLBCL cells, results showed significant inhibition of cell viability. | PMC11551994 |
OCI-LY1 | 200 µM | 1.5 days | To evaluate the cytotoxicity of Bendamustine on DLBCL cells, results showed significant inhibition of cell viability. | PMC11551994 |
CLL-B cells | 0.1, 30, 90 μM | 48 hours | Evaluated cytotoxic effects of bendamustine combined with m15-IgG1 antibody, showing synergistic effects in both high- and low-risk CLL patients. | PMC5438492 |
In Vivo:
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ mice | MCL xenografts | Intraperitoneal injection | 0.5 mg | Two subsequent days every two weeks (2 cycles) | Anti-tumor activity remained comparable between JEKO-1 R clone and JEKO-1 CTRL-xenografted mice | NL-101 |
SCID beige mice | JVM-13 leukemia xenograft model | Intraperitoneal injection | 30 mg/kg | Administered on days 19 and 20, followed by another 2-day cycle 28 days later | Assessed antitumor efficacy of bendamustine alone and in combination with PF-06747143, with the combination group showing enhanced tumor burden reduction and survival benefit. | NL-101 |
SCID or SCID-bg mice | Xenograft models of non-Hodgkin’s lymphoma | Intravenous injection | 25 mg/kg | Single dose | To evaluate the efficacy of Bendamustine alone or in combination with rituximab in non-Hodgkin’s lymphoma models. Results showed that Bendamustine exhibited significant activity in all tested tumor models, with enhanced effects when combined with rituximab. | PMC3575786 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT01570049 | Non-Hodgkin Lymphoma by Clinic... More >>al Course Less << | PHASE3 | UNKNOWN | 2025-12-12 | Tianjin Medical University Can... More >>cer Institute and Hospital, Tianjin, Tianjin, 300060, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, 300060, China Less << |
NCT01929265 | Indolent Non-follicular|Non-Ho... More >>dgkin's Lymphoma Less << | PHASE2 | COMPLETED | 2025-05-15 | SC Ematologia - AO SS. Antonio... More >> e Biagio e C. Arrigo, Alessandria, AL, 15121, Italy|SC Ematologia Spedali Civili, Brescia, BS, Italy|Divisione di Ematologia e Trapianti, Ospedale San Maurizio, Bolzano, BZ, Italy|Divisione di Ematologia, Centro Trapianto di Cellule Staminali, San Giovanni Rotondo, Foggia, Italy|Divisione Ematologia I , Ospedale San Martino, Genova, GE, Italy|S.C. Ematologia Azienda Ospedaliera Papardo, Messina, ME, Italy|Divisione di Oncologia Medica ed Ematologia, Istituto Clinico Humanitas, Rozzano, Milano, Italy|Divisione di Ematologia Ospedale Niguarda, Milano, MI, Italy|Centro Oncologico Modenese, Modena, MO, Italy|Ematologia Azienda Ospedaliero Universitaria Paolo Giaccone, Palermo, PA, Italy|Div. Oncologia Medica - CRO, Centro di Riferimento Oncologico, Aviano, PN, Italy|UOC Ematologia 1/CTMO, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy|Oncoematologia Istituto Pascale, Napoli, Italy|S.C.D.U Ematologia Azienda Ospedaliero Universitaria Maggiore, Novara, Italy|UO Ematologia Università - Policlinico San Matteo, Pavia, Italy|Ematologia Ospedale Santo Spirito, Pescara, Italy|UOA Ematologia, Ospedale Civile Ospedale G. da Saliceto, Piacenza, Italy|Div. Ematologia AO Bianchi Melacrino Morelli, Reggio Calabria, Italy|Ematologia, Azienda Ospedaliera Arcispedale "S.Maria Nuova", Reggio Emilia, Italy|Ematologia, Università "La Sapienza", Roma, Italy|Clinica Ematologia Policlino Le Scotte, Siena, Italy|Struttura Complessa di Onco-Ematologia Azienda Ospedaliera S.Maria, Terni, Italy|SC Ematologia - Città della Salute e della Scienza, Torino, Italy|SC Ematologia U - Città della Salute e della Scienza, Torino, Italy|Clinica Ematologica e Unità di Terapie Cellulari 'Carlo Melzi' AOU S. Maria della Misericordia, Udine, Italy Less << |
NCT00661739 | Metastatic Breast Cancer | PHASE1 | COMPLETED | 2025-05-11 | - |
NCT01701076 | Multiple Myeloma | PHASE2 | COMPLETED | 2025-02-16 | Kantonsspital St. Gallen, St. ... More >>Gallen, 9000, Switzerland Less << |
NCT02315157 | Multiple Myeloma|Plasma Cell L... More >>eukemia Less << | PHASE1 | WITHDRAWN | - | Thomas Jefferson University, P... More >>hiladelphia, Pennsylvania, 19107, United States Less << |
NCT05006469 | Bendamustine|Multiple Myeloma | PHASE3 | UNKNOWN | 2024-05-31 | Shengjing Hospital of China Me... More >>dical University, Shenyang, Liaoning, 110000, China Less << |
NCT00879073 | Brain Metastases | PHASE1 | TERMINATED | 2025-12-12 | H. Lee Moffitt Cancer Center &... More >> Research Institute, Tampa, Florida, 33612, United States Less << |
NCT00959686 | T-cell Lymphoma | PHASE2 | COMPLETED | 2025-02-13 | Dr Gandhi DAMAJ, Amiens, 80054... More >>, France Less << |
NCT03315520 | Relapsed/Refractory Malignant ... More >>Lymphomas Less << | PHASE2 | UNKNOWN | 2020-12-31 | The Federal Budget-Funded Inst... More >>itution National Medical Surgical Center named after N. I. Pirogov of the Ministry of health of the Russian Federation, Moscow, 105203, Russian Federation Less << |
NCT00790855 | Acute Myeloid Leukemia|Myelody... More >>splastic Syndrome|Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia Less << | PHASE1|PHASE2 | TERMINATED | 2025-03-12 | UT MD Anderson Cancer Center, ... More >>Houston, Texas, 77030, United States Less << |
NCT01484626 | Multiple Myeloma | PHASE1|PHASE2 | TERMINATED | 2014-06-18 | Loyola University Medical Cent... More >>er, Maywood, Illinois, 60153, United States Less << |
NCT04127916 | Mantle Cell Lymphoma | UNKNOWN | 2020-12-31 | Samsung Medical Center, 81 Irw... More >>on-ro, Gangnam-gu, Seoul, Republic of Korea, Seoul, 06351, Korea, Republic of|Samsung Medical Center, 81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea, Seoul, 06351, Korea, Republic of Less << | |
NCT01088984 | Leukemia | PHASE1|PHASE2 | COMPLETED | 2025-08-11 | Teva Investigational Site 17, ... More >>Orange, California, United States|Teva Investigational Site 12, San Diego, California, United States|Teva Investigational Site 10, St. Petersburg, Florida, United States|Teva Investigational Site 8, Baltimore, Maryland, United States|Teva Investigational Site 16, Boston, Massachusetts, United States|Teva Investigational Site 9, Detroit, Michigan, United States|Teva Investigational Site 1, Jackson, Mississippi, United States|Teva Investigational Site 5, Kansas City, Missouri, United States|Teva Investigational Site 14, St. Louis, Missouri, United States|Teva Investigational Site 15, New York, New York, United States|Teva Investigational Site 18, Portland, Oregon, United States|Teva Investigational Site 11, Hershey, Pennsylvania, United States|Teva Investigational Site 7, Philadelphia, Pennsylvania, United States|Teva Investigational Site 19, Memphis, Tennessee, United States|Teva Investigational Site 3, Dallas, Texas, United States|Teva Investigational Site 4, Fort Worth, Texas, United States|Teva Investigational Site 13, Houston, Texas, United States|Teva Investigational Site 2, Seattle, Washington, United States|Teva Investigational Site 6, Milwaukee, Wisconsin, United States|Teva Investigational Site 300, Herston, Australia|Teva Investigational Site 301, Parkville, Australia|Teva Investigational Site 302, Randwick, Australia|Teva Investigational Site 520, Minsk, Belarus|Teva Investigational Site 615, Barretos-SP, Brazil|Teva Investigational Site 616, Caxias do Sul, Brazil|Teva Investigational Site 613, Curitiba-PR, Brazil|Teva Investigational Site 612, Porto Alegre, Brazil|Teva Investigational Site 614, Porto Alegre, Brazil|Teva Investigational Site 617, Sao Paulo-SP, Brazil|Teva Investigational Site 610, Sao Paulo, Brazil|Teva Investigational Site 611, Sao Paulo, Brazil|Teva Investigational Site 100, Toronto, Canada|Teva Investigational Site 501, Jerusalem, Israel|Teva Investigational Site 503, Petach Tikva, Israel|Teva Investigational Site 502, Ramat Gan, Israel|Teva Investigational Site 330, Seoul, Korea, Republic of|Teva Investigational Site 331, Seoul, Korea, Republic of|Teva Investigational Site 332, Seoul, Korea, Republic of|Teva Investigational Site 333, Seoul, Korea, Republic of|Teva Investigational Site 603, Guadalajara, Mexico|Teva Investigational Site 600, Mexico City, Mexico|Teva Investigational Site 601, Mexico City, Mexico|Teva Investigational Site 602, Monterrey, Mexico|Teva Investigational Site 303, Auckland, New Zealand|Teva Investigational Site 531, Bialystok, Poland|Teva Investigational Site 530, Lublin, Poland|Teva Investigational Site 532, Warszawa, Poland|Teva Investigational Site 511, Moscow, Russian Federation|Teva Investigational Site 510, St. Petersburg, Russian Federation|Teva Investigational Site 320, Singapore, Singapore Less << |
NCT01649622 | Leukemia|Lymphoma | PHASE2 | WITHDRAWN | - | - |
Tags: Bendamustine | SDX-105 | SDX105 | SDX 105 | DNA Alkylator/Crosslinker | Apoptosis | DNA | purine | alkylating | anticancer | antimetabolite | DNA cross-linking | purine analogue | anticancer | alkylating agent | apoptosis | 16506-27-7
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL